CMO

Craniomandibular osteopathy, commonly referred to as CMO, is a non-neoplastic proliferative bone disease that affects the skull and mandible of growing dogs. The condition is characterized by irregular, excessive new bone formation that replaces normal bone along the jaw, tympanic bullae, and occasionally other regions of the skull. CMO typically appears in puppies between three and eight months of age, coinciding with periods of rapid skeletal development. The abnormal bone growth can be bilateral or unilateral and often causes significant pain and functional impairment.

The disease was first formally described in the veterinary literature in the 1950s and was initially documented predominantly in Scottish terrier breeds. Since that time, CMO has been identified across a broader range of breeds, though it remains most strongly associated with West Highland White Terriers, Scottish Terriers, and Cairn Terriers. The condition is not a form of cancer, despite the alarming appearance of bony masses along the jaw, and it is important for owners to understand that CMO is a self-limiting disease in most cases.

At the cellular level, CMO involves the replacement of normal lamellar bone with irregular woven bone. This process is accompanied by inflammation and periosteal reaction, which contribute to the swelling and pain that characterize the condition. The newly formed bone is structurally disorganized and lacks the orderly architecture of healthy bone tissue, which accounts for its irregular, lumpy appearance on physical examination and radiographic imaging.

The exact mechanism that triggers the aberrant bone remodeling in CMO is not fully understood, but research suggests a genetic basis, particularly in terrier breeds. An autosomal recessive mode of inheritance has been proposed for West Highland White Terriers, and a specific mutation in the SLC37A2 gene has been identified as a contributing factor. The disease process tends to be cyclical, with episodes of active bone proliferation alternating with periods of relative quiescence.

While CMO can be deeply distressing for owners due to the visible jaw swelling and the pain their puppy experiences, the prognosis is generally favorable. In the majority of affected dogs, the abnormal bone growth ceases once skeletal maturity is reached, typically around one year of age. The excess bone may partially or fully remodel over time, and many dogs go on to live normal, comfortable lives following resolution of the active disease phase.

The primary cause of craniomandibular osteopathy is genetic, with strong evidence supporting hereditary transmission in several terrier breeds. Research conducted on West Highland White Terriers has identified an autosomal recessive inheritance pattern, meaning that a puppy must inherit a defective copy of the responsible gene from both parents to develop the disease. The SLC37A2 gene, which encodes a sugar-phosphate transporter involved in bone metabolism, has been implicated as a key genetic factor in the development of CMO in these breeds.

Breed predisposition is the most significant risk factor for CMO. West Highland White Terriers are by far the most commonly affected breed, followed closely by Scottish Terriers and Cairn Terriers. These three breeds share common ancestry, which likely explains the concentration of the genetic mutation within these populations. However, CMO has also been reported in larger breeds including Labrador Retrievers, Great Danes, Doberman Pinschers, Boxers, and English Bulldogs, suggesting that the condition may arise from different genetic mechanisms in different breed lineages.

Age is another important risk factor, as CMO almost exclusively affects young, growing dogs. The onset of clinical signs typically occurs between three and eight months of age, a period during which the skeleton is undergoing rapid growth and remodeling. The developmental nature of the disease means that adult dogs do not develop CMO de novo, although residual bone changes from a juvenile episode may persist into adulthood.

Environmental and nutritional factors have been investigated as potential contributors to CMO, but no consistent associations have been established. Some early hypotheses suggested that dietary imbalances in calcium and phosphorus might play a role, but subsequent research has not supported this theory. Infectious agents, including canine distemper virus, were also considered as potential triggers, but no causal relationship has been confirmed through controlled studies.

There is no known sex predilection for CMO, as male and female puppies appear to be affected with roughly equal frequency. The disease does not appear to be influenced by body condition, activity level, or other management factors. Given the strong genetic basis of the condition, the most effective strategy for reducing its incidence is responsible breeding practices, including genetic testing of breeding stock in predisposed breeds and avoiding mating between known carriers of the SLC37A2 mutation.

The most prominent clinical sign of craniomandibular osteopathy is swelling along the mandible or the base of the skull. Owners typically notice firm, bony enlargements along the lower jaw that may be symmetrical or more pronounced on one side. The swelling is not soft or fluid-filled but rather hard and immovable, reflecting the underlying bony proliferation. In some cases, the tympanic bullae at the base of the skull become significantly enlarged, giving the head an abnormally wide or rounded appearance.

Pain is a hallmark feature of CMO and is often the first sign that prompts veterinary attention. Affected puppies frequently cry out or whimper when their mouth is opened, when they attempt to eat, or when the jaw area is touched. The pain can be episodic, waxing and waning in concert with cycles of active bone proliferation and inflammation. During acute flare-ups, the pain may be severe enough to prevent the puppy from eating altogether, leading to significant weight loss and nutritional deficiency.

Difficulty eating and reluctance to chew are common consequences of the pain and mechanical restriction caused by CMO. As abnormal bone accumulates around the temporomandibular joint, the range of jaw motion may become progressively limited. In severe cases, the excessive bone growth can partially or completely restrict the ability to open the mouth, a condition known as ankylosis of the temporomandibular joint. Puppies affected in this manner may be unable to eat kibble or hard foods and may require softened or liquid diets.

Systemic signs frequently accompany the localized jaw symptoms during active phases of the disease. Affected puppies may develop intermittent fevers, sometimes reaching temperatures of 104 degrees Fahrenheit or higher. Lethargy, decreased appetite, and general malaise are common during febrile episodes. Excessive drooling may be observed due to pain and difficulty swallowing, and some puppies develop halitosis as a secondary consequence of reduced oral hygiene and food accumulation in the mouth.

Less commonly, CMO may affect bones beyond the mandible and tympanic bullae. There have been reports of abnormal bone proliferation involving the long bones of the limbs, though this presentation is rare. When it does occur, affected puppies may exhibit lameness, reluctance to bear weight, or swelling over the affected limb bones. The clinical course of CMO is typically cyclical, with periods of active symptoms lasting several weeks followed by intervals of relative comfort, until the disease process eventually resolves as the puppy approaches skeletal maturity.

Diagnosis of craniomandibular osteopathy begins with a thorough physical examination, during which the veterinarian will palpate the mandible, skull, and temporomandibular joints. The characteristic finding is firm, irregular, non-painful to exquisitely painful bony enlargement along the ventral mandible or around the tympanic bullae. The breed, age, and clinical presentation of the patient often provide strong initial suspicion for CMO, particularly in terrier breed puppies presenting with jaw swelling and pain.

Radiographic imaging is the primary diagnostic tool for confirming CMO. Skull radiographs typically reveal bilateral, irregular periosteal new bone formation along the mandible, with the tympanic bullae frequently involved. The radiographic appearance is distinctive, showing dense, irregular bony proliferation that contrasts with the smooth cortical surface of normal bone. In some cases, the temporomandibular joint space may be obscured by the surrounding new bone. Radiographs also help assess the extent of the disease and identify involvement of additional skull bones.

Advanced imaging modalities such as computed tomography provide superior detail compared to standard radiography and may be recommended in complex or severe cases. CT scanning offers three-dimensional visualization of the bony changes and is particularly useful for evaluating the degree of temporomandibular joint involvement and planning potential surgical interventions. CT can also help differentiate CMO from other conditions that may produce similar radiographic appearances, including neoplasia and osteomyelitis.

Laboratory testing in dogs with CMO may reveal nonspecific findings consistent with systemic inflammation. Complete blood count may show mild leukocytosis and elevated acute-phase proteins during active disease episodes. Serum alkaline phosphatase levels may be elevated, reflecting increased bone turnover, though this finding is common in growing puppies regardless of CMO status. These laboratory abnormalities are supportive but not diagnostic on their own.

In atypical cases where the diagnosis remains uncertain, bone biopsy may be performed to obtain a definitive histopathological diagnosis. Biopsy specimens from CMO-affected bone characteristically show irregular woven bone replacing normal lamellar bone, with associated periosteal inflammation and fibrous tissue proliferation. Biopsy is particularly important when the clinical presentation is unusual, the patient is of an uncommon breed for CMO, or there is concern about neoplastic bone disease. Genetic testing for the SLC37A2 mutation is available for West Highland White Terriers and can confirm carrier status in breeding animals, though it is not routinely used as a diagnostic tool in clinically affected puppies.

There is no specific treatment that halts or reverses the abnormal bone growth in craniomandibular osteopathy. Management of CMO is therefore focused on controlling pain, maintaining adequate nutrition, and supporting the puppy through the active phase of the disease until spontaneous resolution occurs at skeletal maturity. The cornerstone of medical management is anti-inflammatory and analgesic therapy, which can dramatically improve the quality of life of affected puppies during painful episodes.

Non-steroidal anti-inflammatory drugs such as meloxicam or carprofen are commonly prescribed as first-line pain management for CMO. These medications reduce inflammation and provide analgesia, helping affected puppies eat more comfortably and maintain normal activity levels. In cases where NSAIDs alone are insufficient to control pain, corticosteroids such as prednisone may be used during acute flare-ups. Corticosteroids are potent anti-inflammatory agents that can provide substantial pain relief, but their long-term use carries risks including immunosuppression, gastrointestinal side effects, and interference with normal growth in young animals.

Nutritional support is a critical component of CMO management, particularly for puppies experiencing significant difficulty eating. Softened food, gruel, or liquid diets may be necessary during periods of severe jaw pain or restricted mouth opening. Owners should ensure that caloric intake remains adequate to support normal growth and development. In severe cases where the puppy is unable to eat sufficient quantities orally, temporary placement of a feeding tube may be considered to prevent malnutrition and dehydration.

Additional analgesic medications may be incorporated into the treatment plan for puppies with severe or refractory pain. Gabapentin, tramadol, and other adjunctive pain medications can be used in combination with NSAIDs or corticosteroids to achieve multimodal analgesia. The specific combination and dosing of pain medications should be tailored to the individual patient and adjusted based on clinical response. Regular veterinary follow-up is important to monitor the effectiveness of pain management and make necessary adjustments.

Surgical intervention is rarely required for CMO but may be considered in cases where severe temporomandibular joint ankylosis develops and persists beyond skeletal maturity. Surgical options include excision of the excessive bone to restore jaw mobility, though this procedure carries significant risks including damage to adjacent structures and potential recurrence of bony proliferation. Physical therapy and gentle jaw stretching exercises may be recommended in conjunction with medical management to help maintain range of motion in the temporomandibular joint during the active disease phase.

The prognosis for dogs with craniomandibular osteopathy is generally good, as the disease is self-limiting in the majority of cases. The abnormal bone proliferation typically ceases once the dog reaches skeletal maturity, usually between 11 and 13 months of age. Following cessation of active bone growth, the excess bone may undergo partial or complete remodeling, resulting in gradual improvement in the appearance and function of the jaw over subsequent months.

The degree of functional recovery varies considerably among individual dogs and depends largely on the severity and location of the bony changes. Dogs with mild to moderate CMO that does not significantly involve the temporomandibular joint typically experience complete or near-complete functional recovery. These dogs can eat normally, play, and carry toys without difficulty once the active phase has resolved. Owners of mildly affected dogs may notice residual bony thickening along the mandible that persists as a cosmetic finding but does not cause functional impairment.

In contrast, dogs with severe CMO involving significant temporomandibular joint ankylosis face a more guarded prognosis. If the abnormal bone growth fuses the temporomandibular joint or severely restricts jaw mobility, the dog may have permanent difficulty opening its mouth fully. These dogs may require long-term dietary modifications, such as a permanently softened diet, and may be unable to perform normal oral behaviors like chewing bones or carrying large objects. Severe ankylosis cases occasionally require surgical intervention to improve jaw function.

The long-term health of dogs that have recovered from CMO is generally excellent. There is no evidence that CMO predisposes affected dogs to other bone diseases or increases the risk of skeletal neoplasia later in life. Dogs that have fully recovered from CMO have normal life expectancies and do not typically require ongoing medical management for the condition. However, owners should be aware that carriers of the CMO-associated genetic mutation can pass the trait to their offspring.

Euthanasia is rarely necessary for dogs with CMO but may be considered in extreme cases where severe, uncontrollable pain persists despite aggressive medical management, or where complete jaw ankylosis renders the dog unable to eat even with dietary modification. These outcomes are uncommon with appropriate veterinary care, and the vast majority of CMO-affected puppies go on to lead full, comfortable lives following resolution of the active disease phase.

West Highland White Terriers are the breed most strongly associated with craniomandibular osteopathy, and the condition has been extensively studied in this breed. The autosomal recessive inheritance pattern identified in Westies means that both parents must carry the defective SLC37A2 gene for a puppy to be affected. Genetic testing is available for this breed, allowing breeders to identify carriers and make informed breeding decisions to reduce the incidence of CMO in future generations. Responsible Westie breeders are encouraged to test breeding stock and avoid carrier-to-carrier matings.

Scottish Terriers and Cairn Terriers share close genetic heritage with West Highland White Terriers, and CMO occurs in these breeds with notable frequency as well. The clinical presentation in Scottish Terriers and Cairn Terriers is generally similar to that seen in Westies, with mandibular and tympanic bullae involvement being the most common pattern. The genetic basis of CMO in these breeds is believed to involve the same or closely related genetic loci as in West Highland White Terriers, though breed-specific genetic testing may not be as widely available.

CMO in large and giant breeds such as Labrador Retrievers, Great Danes, Boxers, and Doberman Pinschers presents somewhat differently than in terrier breeds. Large-breed dogs with CMO may exhibit more extensive bony proliferation and may be more likely to develop involvement of the long bones in addition to the skull. The genetic basis of CMO in these breeds is less well characterized, and the inheritance pattern may differ from the autosomal recessive mode identified in terriers. Clinicians should maintain a higher index of suspicion for alternative diagnoses, including hypertrophic osteodystrophy, when evaluating large-breed puppies with bony proliferative changes.

Bulldog breeds, including English Bulldogs and Boston Terriers, have also been reported to develop CMO. The brachycephalic skull conformation in these breeds can complicate both the clinical presentation and the diagnostic imaging of CMO. The pre-existing anatomical variations in skull shape may make it more challenging to identify early bony changes on radiographs, and the altered biomechanics of the brachycephalic jaw may influence the functional impact of the disease.

Regardless of breed, all dogs diagnosed with CMO should be considered unsuitable for breeding purposes. Even dogs that fully recover from CMO carry the genetic predisposition and are capable of producing affected offspring if mated with another carrier. Breed clubs and registries for predisposed breeds increasingly recognize CMO as a significant hereditary health concern and may maintain registries of affected dogs to assist breeders in making responsible mating decisions.

Several conditions can produce clinical signs similar to CMO and must be considered in the differential diagnosis when evaluating a young dog with jaw swelling and pain. Osteosarcoma, the most common primary bone tumor in dogs, can cause bony proliferation and swelling of the mandible. However, osteosarcoma is predominantly a disease of middle-aged to older dogs and is relatively rare in the young age group typically affected by CMO. Radiographic features of osteosarcoma, including aggressive bone lysis and a sunburst periosteal reaction, differ from the characteristic dense proliferative pattern seen in CMO.

Osteomyelitis, or infection of the bone, is another important differential diagnosis. Bacterial osteomyelitis of the mandible can result from dental disease, bite wounds, or hematogenous spread of infection. Affected dogs present with jaw swelling, pain, and sometimes draining tracts or fistulae. Radiographic findings in osteomyelitis may include both lytic and proliferative bone changes, and the presence of sequestra or involucra can help distinguish infection from CMO. Culture and sensitivity testing of biopsy specimens may be necessary to confirm a diagnosis of osteomyelitis.

Hypertrophic osteodystrophy is a developmental bone disease that primarily affects the metaphyseal regions of long bones in young, rapidly growing large-breed dogs. While HOD does not typically involve the skull, it can coexist with CMO in some cases, particularly in large-breed dogs. HOD is characterized by irregular radiolucent lines in the metaphyses, periosteal new bone formation, and systemic signs including fever and lethargy. The distinction between HOD and CMO is usually straightforward based on the anatomical distribution of lesions, but overlap cases require careful evaluation.

Panosteitis, another developmental bone condition of young dogs, causes shifting leg lameness and pain on palpation of long bone diaphyses. Panosteitis does not affect the skull and is therefore unlikely to be confused with CMO based on physical examination findings. However, if a puppy with CMO also exhibits limb pain, panosteitis should be considered as a concurrent condition. Radiographic findings of panosteitis, including increased medullary density within the diaphysis of affected long bones, are distinct from those of CMO.

Masticatory muscle myositis, an immune-mediated inflammatory condition affecting the muscles of mastication, can present with jaw pain, difficulty eating, and swelling of the temporal and masseter muscles. Unlike the hard, bony swelling of CMO, the swelling in masticatory myositis is soft tissue in nature and involves muscle rather than bone. Advanced cases of masticatory myositis may result in muscle atrophy and fibrosis, leading to restricted jaw motion that can mimic the ankylosis seen in severe CMO. Serologic testing for antibodies against type 2M myosin fibers can confirm the diagnosis of masticatory myositis.

Caring for a puppy diagnosed with craniomandibular osteopathy requires patience, attentiveness, and consistent communication with the veterinary care team. The episodic nature of the disease, with its cycles of painful flare-ups and relative comfort, can be emotionally taxing for owners who must watch their puppy experience recurring periods of distress. Understanding the self-limiting nature of CMO and maintaining realistic expectations about the timeline for resolution can help owners navigate the challenges of managing the condition.

Pain monitoring is an essential daily responsibility for owners of CMO-affected puppies. Signs of pain may include reluctance to eat, whimpering when yawning or opening the mouth, head shyness, decreased playfulness, and changes in behavior such as withdrawal or irritability. Owners should maintain a log of pain episodes, noting their frequency, duration, and severity, as this information is valuable for guiding adjustments to the pain management protocol. Any sudden worsening of symptoms or the appearance of new clinical signs should prompt veterinary evaluation.

Environmental modifications can enhance the comfort of puppies living with CMO. Food and water bowls should be elevated to a comfortable height to reduce the need for excessive neck flexion. Hard toys, bones, and chew items should be removed from the environment during active disease phases to prevent exacerbation of jaw pain. Soft, plush toys may be offered as alternatives for puppies that enjoy carrying objects. Bedding should be soft and supportive, and the sleeping area should be kept warm, as cold environments may exacerbate discomfort.

Socialization and mental stimulation remain important for CMO-affected puppies, who are still in a critical developmental period for behavioral learning. While physical activities that involve the mouth, such as tug-of-war and fetch with hard toys, should be avoided during painful episodes, other forms of enrichment can be safely provided. Gentle training sessions using soft treats, sensory enrichment through novel scents and sounds, and calm social interactions with people and other dogs can help maintain normal behavioral development despite the limitations imposed by the disease.

Follow-up veterinary appointments should be scheduled at regular intervals throughout the active phase of CMO, typically every four to six weeks. These visits allow the veterinarian to assess disease progression, evaluate the effectiveness of pain management, monitor growth and nutritional status, and obtain follow-up radiographs when indicated. As the puppy approaches skeletal maturity, the frequency of flare-ups should diminish and eventually cease, at which point the veterinarian can confirm resolution of the active disease and discuss any long-term management considerations.

Prevention of craniomandibular osteopathy centers on responsible breeding practices and genetic testing in predisposed breeds. The identification of the SLC37A2 gene mutation as a causative factor in West Highland White Terriers has enabled the development of a commercially available DNA test that can determine whether an individual dog is clear, a carrier, or affected. Breeders of West Highland White Terriers are strongly encouraged to test all breeding animals and to use the results to guide mating decisions that minimize the production of affected puppies.

The recommended breeding strategy when using genetic test results follows standard principles for autosomal recessive conditions. Mating two clear dogs produces only clear offspring. Mating a clear dog with a carrier produces puppies that are either clear or carriers, but none that are affected. Mating two carriers results in a statistical expectation of 25 percent affected puppies, 50 percent carriers, and 25 percent clear dogs. Carrier-to-carrier matings should be avoided whenever possible to reduce the incidence of CMO in the breed.

For breeds in which the specific genetic mutation responsible for CMO has not been identified, prevention relies on phenotypic screening and pedigree analysis. Breeders should maintain accurate records of CMO diagnoses within their breeding lines and avoid repeating matings that have previously produced affected offspring. Open health registries and breed club databases can facilitate information sharing among breeders and help identify lines with higher rates of CMO occurrence.

Prospective puppy buyers can take several steps to reduce their risk of acquiring a CMO-affected puppy. Selecting a breeder who performs genetic testing on their breeding stock and can provide documentation of test results is the most effective strategy for Westie buyers. For other predisposed breeds, buyers should inquire about the health history of the breeding line, including any previous diagnoses of CMO in related dogs. Purchasing from breeders who participate in breed health surveys and contribute to open health databases demonstrates a commitment to breed health improvement.

It is important to recognize that genetic testing, while powerful, cannot eliminate CMO entirely from predisposed breeds in a single generation. Carriers of the mutation are clinically normal and may be valuable breeding animals in other respects, such as conformation, temperament, and performance. A balanced approach that considers overall breed health and genetic diversity, rather than focusing exclusively on CMO status, will produce the best long-term outcomes for breed populations. Genetic counseling services offered by veterinary geneticists and breed clubs can help breeders navigate these complex decisions.